Intellia Therapeutics expands ATM equity facility from $400M to $750M

Intellia Therapeutics, Inc.

Intellia increased at-the-market equity offering facility from $400M to $750M via amendment to Jefferies Sales Agreement.
As of 2/23/24, ~$374M of shares sold; additional $350M authorized under new prospectus supplement.
Remaining unsold shares under existing prospectus: ~$25.7M.
Jefferies LLC continues as sales agent, receiving 3.0% of gross proceeds.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Intellia Therapeutics, Inc. amended Sales Agreement with Jefferies LLC valued at increase from $400,000,000 to $750,000,000 (effective 2024-02-23).

Action: amendment
Agreement: atm program
Counterparty: Jefferies LLC
Value: increase from $400,000,000 to $750,000,000
Effective: 2024-02-23

Exact text from the filing

On February 23, 2024, the Company entered into an amendment to the Sales Agreement to increase the size of the at-the-market offering program from $400,000,000 to $750,000,000.

View on SEC.gov

Browse all material agreements →

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-044690

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.